{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:36:40Z","timestamp":1789472200386,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021778","name":"Agencia Nacional de Promoci\u00f3n de la Investigaci\u00f3n, el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n","doi-asserted-by":"publisher","award":["23-A-17"],"award-info":[{"award-number":["23-A-17"]}],"id":[{"id":"10.13039\/501100021778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10147-023-02393-z","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:02:06Z","timestamp":1690848126000},"page":"1411-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-3747","authenticated-orcid":false,"given":"Tsukasa","family":"Baba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Koshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kagabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzuko","family":"Moritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Katabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyomi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"2393_CR1","unstructured":"Japan Society of Gynecologic Oncology, ed. Ovarian cancer treatment guidelines 2010 (in Japanese). Kanehara & Co. Ltd, Tokyo. 97\u2013106."},{"key":"2393_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","volume":"29","author":"TA Longacre","year":"2005","unstructured":"Longacre TA, McKenney JK, Tazelaar HD et al (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29:707\u2013723. PMID: 15897738","journal-title":"Am J Surg Pathol"},{"key":"2393_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1097\/00000478-200209000-00002","volume":"26","author":"J Prat","year":"2002","unstructured":"Prat J, De Nictolis M (2002) Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 26:1111\u20131128","journal-title":"Am J Surg Pathol"},{"key":"2393_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/hp.2000.8048","volume":"31","author":"JD Seidman","year":"2000","unstructured":"Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539\u2013557","journal-title":"Hum Pathol"},{"key":"2393_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1634\/theoncologist.2008-0263","volume":"14","author":"A Kane","year":"2009","unstructured":"Kane A, Uzan C, Rey A et al (2009) Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist 14:591\u2013600","journal-title":"Oncologist"},{"key":"2393_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","volume":"30","author":"EG Silva","year":"2006","unstructured":"Silva EG, Gershenson DM, Malpica A et al (2006) The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 30:1367\u20131371","journal-title":"Am J Surg Pathol"},{"key":"2393_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/annonc\/mdp267","volume":"21","author":"C Uzan","year":"2010","unstructured":"Uzan C, Kane A, Rey A et al (2010) Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 21:55\u201360","journal-title":"Ann Oncol"},{"key":"2393_CR8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/sj.bjc.6603139","volume":"94","author":"Y Yokoyama","year":"2006","unstructured":"Yokoyama Y, Moriya T, Takano T et al (2006) Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 94:1586\u20131591","journal-title":"Br J Cancer"},{"key":"2393_CR9","first-page":"155","volume":"30","author":"K Kokawa","year":"2009","unstructured":"Kokawa K, Mikami Y, Sakata H et al (2009) Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years\u2019 experience in the Kinki District of Japan (1990\u20132006). Eur J Gynaecol Oncol 30:155\u2013161","journal-title":"Eur J Gynaecol Oncol"},{"key":"2393_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/0284186X.2019.1619935","volume":"58","author":"MS Schuurman","year":"2019","unstructured":"Schuurman MS, Timmermans M, van Gorp T et al (2019) Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis. Acta Oncol 58:983\u2013989","journal-title":"Acta Oncol"},{"key":"2393_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/IGC.0b013e31824b4076","volume":"22","author":"T Song","year":"2012","unstructured":"Song T, Lee YY, Choi CH et al (2012) Prognosis in patients with serous and mucinous stage I borderline ovarian tumors. Int J Gynecol Cancer 22:770\u2013777","journal-title":"Int J Gynecol Cancer"},{"key":"2393_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/his.13651","volume":"73","author":"G Turashvili","year":"2018","unstructured":"Turashvili G, Grisham RN, Chiang S et al (2018) BRAF(V)(600E) mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary. Histopathology 73:438\u2013443","journal-title":"Histopathology"},{"key":"2393_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000336140","volume":"35","author":"N Ewald-Riegler","year":"2012","unstructured":"Ewald-Riegler N, du Bois O, Fisseler-Eckhoff A et al (2012) Borderline tumors of the ovary: clinical course and prognostic factors. Onkologie 35:28\u201333","journal-title":"Onkologie"},{"key":"2393_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/humrep\/dez307","volume":"35","author":"SZ Jia","year":"2020","unstructured":"Jia SZ, Xiang Y, Yang JJ et al (2020) Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study. Hum Reprod 35:328\u2013339","journal-title":"Hum Reprod"},{"key":"2393_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ygyno.2020.02.007","volume":"157","author":"H Plett","year":"2020","unstructured":"Plett H, Harter P, Ataseven B et al (2020) Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol 157:411\u2013417","journal-title":"Gynecol Oncol"},{"key":"2393_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/PAS.0000000000000824","volume":"41","author":"R Vang","year":"2017","unstructured":"Vang R, Hannibal CG, Junge J et al (2017) Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases. Am J Surg Pathol 41:725\u2013737","journal-title":"Am J Surg Pathol"},{"key":"2393_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ygyno.2011.08.008","volume":"123","author":"JY Park","year":"2011","unstructured":"Park JY, Kim DY, Kim JH et al (2011) Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol 123:511\u2013516","journal-title":"Gynecol Oncol"},{"key":"2393_CR18","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1097\/PAS.0000000000001325","volume":"43","author":"MH Chui","year":"2019","unstructured":"Chui MH, Xing D, Zeppernick F et al (2019) Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma. Am J Surg Pathol 43:1462\u20131472","journal-title":"Am J Surg Pathol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02393-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:07:21Z","timestamp":1695946041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02393-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02393-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3070835\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was designed and executed by the participating and standby centers of the JCOG Gynecologic Oncology Group. The authors declare no conflicts of interest associated with any particular company. The National Cancer Center Research and Development Fund (23-A-17) was involved in the collection and analysis of data, CPR, writing of the report, and decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest and Sources of Funding"}}]}}